Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | ACACA | Q13085 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 8/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemcabene SCHEMBL761631 | 0.90 | ACLY (0.55) | ACLYACACBACACAPPARATTR | |
| SCHEMBL5531453 | 0.88 | ACLY (0.59) | ACLYACACBACACAPPARATTR | |
| SCHEMBL14269711 | 0.88 | ACLY (0.59) | ACLYACACBACACAPPARATTR | |
| Gemcabene SCHEMBL528316 | 0.88 | ACLY (0.53) | ACLYACACBACACAPPARATTR | |
| Gemcabene SCHEMBL4184554 | 0.88 | ACLY (0.53) | ACLYACACBACACAPPARATTR | |
| SCHEMBL6258161 | 0.88 | ACLY (0.53) | ACLYACACBACACAPPARATTR | |
| SCHEMBL5524941 | 0.88 | ACLY (0.59) | ACLYACACBACACAPPARATTR | |
| SCHEMBL10870601 | 0.88 | ACLY (0.57) | ACLYACACBACACAPPARATTR | |
| SCHEMBL6267270 | 0.86 | ACLY (0.52) | ACLYACACBACACAPPARATTR | |
| SCHEMBL5521484 | 0.86 | ACLY (0.57) | ACLYACACBACACAPPARATTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110996928-A | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof, and methods of use thereof | 燿石治疗公司 | 2020-04-10 | — | — | CN | claimed |
| EP-3612171-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | Gemphire Therapeutics Inc. (US) | 2020-02-26 | — | — | EP | claimed |
| WO-2018195163-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | GEMPHIRE THERAPEUTICS INC. (US) | 2018-10-25 | — | — | WO | claimed |
| US-12503422-B2 | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | NEUROBO PHARMACEUTICALS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20220332672-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | NEUROBO PHARMACEUTICALS INC (US) | 2022-10-20 | — | — | US | disclosed |
| WO-2022147499-A1 | METHOD OF TREATING VIRAL INFECTIONS WITH A COMBINATION OF NICLOSAMIDE AND GEMCABENE | NEUROBO PHARMACEUTICALS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| CN-113396138-A | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof, and methods of use thereof | 燿石治疗公司 | 2021-09-14 | — | — | CN | disclosed |
| US-20200253877-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | NEUROBO PHARMACEUTICALS, INC. | 2020-08-13 | — | — | US | disclosed |
| US-20200148617-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | NEUROBO PHARMACEUTICALS, INC. | 2020-05-14 | — | — | US | disclosed |
| WO-2020081837-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | GEMPHIRE THERAPEUTICS INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| CN-110996928-A | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof, and methods of use thereof | 燿石治疗公司 | 2020-04-10 | — | — | CN | disclosed |
| EP-3612171-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | Gemphire Therapeutics Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| WO-2018195163-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | GEMPHIRE THERAPEUTICS INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-20180297929-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | NEUROBO PHARMACEUTICALS, INC. | 2018-10-18 | — | — | US | disclosed |
| US-7777071-B2 | Production of carnitine conjugate intermediates | SSV THERAPEUTICS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090012160-A1 | Carnitine Conjugates As Dual Prodrugs, Methods Of Production And Uses Thereof | SSV THERAPEUTICS, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2008018877-A1 | CARNITINE CONJUGATES AS DUAL PRODRUGS, METHODS OF PRODUCTION AND USES THEREOF | SSV THERAPEUTICS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008018877-A1 | CARNITINE CONJUGATES AS DUAL PRODRUGS, METHODS OF PRODUCTION AND USES THEREOF | SSV THERAPEUTICS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332672-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | NPC1L1, NOTUM, CEL | ACLY 2298/4885ACACB 1237/4885ACACA 1161/4885 |
| US-20090012160-A1 | Carnitine Conjugates As Dual Prodrugs, Methods Of Production And Uses Thereof | CPT1B, CRAT, CPT2 | ACLY 393/4885ACACB 725/4885ACACA 796/4885 |
| US-20200148617-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | NPC1L1, NOTUM, CEL | ACLY 2298/4885ACACB 1237/4885ACACA 1161/4885 |
| US-20200253877-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | PKD1, SLC10A1, TGFB1 | ACLY 2894/4885ACACB 1112/4885ACACA 581/4885 |
| US-12503422-B2 | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor | NPC1L1, NOTUM, CEL | ACLY 2298/4885ACACB 1237/4885ACACA 1161/4885 |
| US-20180297929-A1 | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | NPC1L1, NOTUM, CEL | ACLY 2298/4885ACACB 1237/4885ACACA 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.